Drug maker Concordia in talks to sell stake to private equity firm: Reuters
Concordia International Corp, a Canadian specialty pharmaceutical company, is discussing alternatives to a leveraged buyout that include divesting a minority stake to a private equity firm, sources told Reuters. The sale would raise cash to ease the burden of Concordia's US$3 billion in debt as it faces curbs on drug pricing from governments and companies. The latest round of talks comes after negotiations about selling the company outright failed to produce a deal that would be acceptable to its board, the sources said.
3 October 2016•2 mins read
